Alzheimer's disease

Neurobiology of Disease

Volumn , Issue , 2007, Pages 69-82

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37549008061     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50008-6     Document Type: Chapter

References (39)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgem. Z. Psychiatr. 1907, 64:146-148.
2. Bick K.L. The early history of Alzheimer' s disease. Alzheimer Disease 1999, 1-9. Lippincott, Williams and Wilkins, Philadelphia. R.D. Terry, R. Katzman, K.L. Bick, S.S. Sisodia (Eds.).
3. Alzheimer A. Ueber eigenartige Krankheitsfaelle des spaeteren Alters. Z. Ges. Neurol. Psychiatrie 1911, 4:356-385.
4. Knopman D.S. Alzheimer type dementia. Neurodegenera- tion: The Molecular Pathology of Dementia and Movement Disorders 2003, 24-39. ISN Neuropath Press, Basel. D.W. Dickson (Ed.).
5. Hardy J. Genetics of Alzheimer's disease and related disorders. Current Clinical Neurology. Alzheimer's Disease: A Physician's Guide to Practical Management 2004, 3-20. Humana Press, Totowa, NJ. R.W. Richter, B. Zoeller-Richter (Eds.).
6. Masters C.L., Beyreuther K. Molecular pathogenesis of Alzheimer's disease. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2003, 69-73. ISN Neuropath Press, Basel. D.W. Dickson (Ed.).
7. Roy S., Zhang B., Lee V.M., Trojanowski J.Q. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. (Berl) 2005, 109:5-13.
8. Cotman C.W., Poon W.W., Rissman R.A., Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J. Neuropatho.l Exp. Neurol. 2005, 64:12-104.
9. Mattson M.P., Magnus T. Ageing and neuronal vulner-ability. Nat. Rev. Neurosci. 2006, 7:94-278.
10. McGowan E., Pickford F., Dickson D.W. Alzheimer animal models: models of A-beta deposition in transgenic mice. In "Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2003, 74-79. ISN Neuropath Press, Basel. D.W. Dickson (Ed.).
11. Markesbery W.R., Kryscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58:5-730.
12. Jellinger K.A. Apoptosis vs nonapoptotic mechanisms in neurodegeneration. Neuroinflammation 2003, 29-88. Humana Press, Totowa, NJ. 2nd Edition. P.L. Wood (Ed.).
13. Duyckaerts C., Dickson D.W. Neuropathology of Alzheimer's disease. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2003, 47-65. ISN Neuropath Press, Basel. D.W. Dickson (Ed.).
14. Alzheimer Disease 1999, Lippincott, Williams and Wilkins, Philadelphia. R.D. Terry, R. Katzman, K.L. Bick, S.S. Sisodia, (Eds.).
15. Jellinger K.A. A view on early diagnosis of dementias from neuropathology. Early Diagnosis of Dementias 2006, 311-428. Marcel Dekker, New York. K. Herholz, C. Morris, D. Perani (Eds.).
16. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
17. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82:239-259.
18. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Nonoverlap-ping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002, 59:398-407.
19. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:800-1791.
20. Mirra S.S., Hyman B.T. Aging and dementia. Green- field's Neuropathology 2002, 195-271. E. Arnold, London. 7th Ed. D.I. Graham, P.L. Lantos (Eds.).
21. McKeel D.W., Price J.L., Miller J.P., Grant E.A., Xiong C., Berg L., Morris J.C. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J. Neuropathol. Exp. Neurol. 2004, 63:1028-1037.
22. Tiraboschi P., Sabbagh M.N., Hansen L.A., Salmon D.P., Merdes A., Gamst A., Masliah E., Alford M., Thal L.J., Corey-Bloom J. Alzheimer disease without neocortical neurofibril-lary tangles: "a second look.". Neurology 2004, 62:1141-1147.
23. Attems J., Lintner F., Jellinger K.A. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. (Berl) 2004, 107:283-291.
24. Wirths O., Multhaup G., Bayer T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem. 2004, 91:513-520.
25. Markesbery W.R., Schmitt F.A., Kryscio R.J., Davis D.G., Smith C.D., Wekstein D.R. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006, 63:38-46.
26. Riley K.P., Snowdon D.A., Markesbery W.R. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann. Neurol. 2002, 51:567-577.
27. Katsuno T., Morishima-Kawashima M., Saito Y., Yamanouchi H., Ishiura S., Murayama S., Ihara Y. Independent accumu-lations of tau and amyloid beta-protein in the human entorhinal cortex. Neurology 2005, 64:687-692.
28. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
29. Gsell W., Jungkunz G., Riederer P. Functional neurochemistry of Alzheimer's disease. Curr. Pharm. Design 2003, 9:265-293.
30. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging 2003, 24:1-23.
31. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
32. Mild Cognitive Impairment: Aging to Alzheimer's Disease 2003, Oxford University Press, Oxford, UK. R.C. Petersen, (Ed.).
33. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51:145-155.
34. Renner J.A., Burns J.M., Hou C.E., McKeel D.W., Storandt M., Morris J.C. Progressive posterior cortical dysfunc-tion: a clinicopathologic series. Neurology 2004, 63:1175-1180.
35. Alzheimer's Disease: A Physician's Guide to Practical Management 2005, Humana Press, Totowa, NJ. R.W. Richter, B. Zoeller-Richter, (Eds.).
36. Lleo A., Greenberg S.M., Growdon J.H. Current phar-macotherapy for Alzheimer's disease. Annu. Rev. Med. 2006, 57:513-533.
37. Dantoine T., Auriacombe S., Sarazin M., Becker H., Pere J.J., Bourdeix I. Rivastigmine monotherapy and combina-tion therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous ch. Int. J. Clin. Pract. 2006, 60:110-118.
38. Citron M. Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5:677-685.
39. Jelic V., Kivipelto M., Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry 2006, 77:429-438.